[1]刘建华,王俊利,程蒋,等.非他汀类降脂药物研究现状[J].国际心血管病杂志,2022,06:337-340.
点击复制
非他汀类降脂药物研究现状(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年06期
- 页码:
- 337-340
- 栏目:
- 综述
- 出版日期:
- 2022-12-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.06.005
- 文献标识码:
- -
- 摘要:
- 中国成人血脂异常的患病率高达40.4%，而一线他汀类降脂药物效果并不理想， 需要非他汀类药物进一步降低心血管事件风险。该文介绍非他汀类药物的降脂靶点、降脂 机制及应用现状，并介绍部分相关药物包括inclisiran、evinacumab、obicetrapib、bempedoic acid、AKCEA-APO(a)-LRx、olpasiran、volanesorsen、Vascepa 等的作用机制、疗效、安全 性及临床试验进展。
- Abstract:
- -
参考文献/References
[1] 顾景范. 《中国居民营养与慢性病状况报告(2015)》解读
[J]. 营养学报, 2016, 38(6):525-529.
[2] Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease
in U.S. deaths from coronary disease, 1980-2000[J]. N Engl J
Med, 2007, 356(23):2388-2398.
[3] 中国成人血脂异常防治指南修订联合委员会. 中国成人血
脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016,
31(10):937-950.
[4] Zhao SP, Yu BL, Peng DQ, et al. The effect of moderatedose
versus double-dose statins on patients with acute
coronary syndrome in China: results of the CHILLAS trial[J].
Atherosclerosis, 2014, 233(2):707-712.
[5] Chiang CE, Ferrières J, Gotcheva NN, et al. Suboptimal
control of lipid levels: results from 29 countries participating
in the centralized pan-regional surveys on the undertreatment
of hypercholesterolaemia (CEPHEUS)[J]. J Atheroscler
Thromb, 2016, 23(5):567-587.
[6] Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity,
and risk factors in China and its provinces, 1990-2017: a
systematic analysis for the Global Burden of Disease Study
2017[J]. Lancet, 2020, 394(10204):1145-1158.
[7] Jaworski K, Jankowski P, Kosior DA. PCSK9 inhibitors—
from discovery of a single mutation to a groundbreaking
therapy of lipid disorders in one decade[J]. Arch Med Sci,
2017, 13(4):914-929.
[8] Levin AA. Treating disease at the RNA level with
oligonucleotides[J]. N Engl J Med, 2019, 380(1):57-70.
[9] Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of
inclisiran in patients with elevated LDL cholesterol [J]. N Engl
J Med, 2020, 382(16):1507-1519.
[10] Ruscica M, Zimetti F, Adorni MP, et al. Pharmacological
aspects of ANGPTL3 and ANGPTL4 inhibitors: new
therapeutic approaches for the treatment of atherogenic
dyslipidemia[J]. Pharmacol Res, 2020, 153:104653.
[11] Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for
homozygous familial hypercholesterolemia[J]. N Engl J Med,
2020, 383(8):711-720.
[12] Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl
ester transfer protein inhibitors: from high-density lipoprotein
cholesterol to low-density lipoprotein cholesterol lowering
agents?[J]. Cardiovasc Res, 2022, 118(14):2919-2931.
[13] 王其琼, 刘蕾. 新型口服降脂药物——Bempedoic Acid[J].
临床药物治疗杂志, 2021, 19(1):26-30.
[14] Marrs JC, Anderson SL. Bempedoic acid for the treatment of
dyslipidemia[J]. Drugs Context, 2020, 9:2020-6-5.
[15] Berg K. A new serum type system in man—the Lp system[J].
Acta Pathol Microbiol Scand, 1963, 59:369-382.
[16] Berg K, Mohr J. Genetics of the Lp system[J]. Acta Genet Stat
Med, 1963, 13:349-360.
[17] Mohr J, Reinskou T. Genetics of the Gc serum types:
associations and linkage relations[J]. Acta Genet Stat Med,
1963, 13:328-333.
[18] Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated
Lp(a) mass levels and patient thresholds in 532 359 patients
in the United States[J]. Arterioscler Thromb Vasc Biol, 2016,
36(11):2239-2245.
[19] Tsimikas S. A test in context: lipoprotein(a): diagnosis,
prognosis, controversies, and emerging therapies[J]. J Am Coll
Cardiol, 2017, 69(6):692-711.
[20] Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I,
et al. Lipoprotein(a) reduction in persons with cardiovascular
disease[J]. N Engl J Med, 2020, 382(3):244-255.
[21] Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical
development and phase 1 trial of a novel siRNA targeting
lipoprotein(a)[J]. Nat Med, 2022, 28(1):96-103.
[22] Hegele RA, Tsimikas S. Lipid-lowering agents[J]. Circ Res,
2019, 124(3):386-404.
[23] Ebara T, Ramakrishnan R, Steiner G, et al. Chylomicronemia
due to apolipoprotein CⅢ overexpression in apolipoprotein
E-null mice. Apolipoprotein CⅢ-induced hypertriglyceridemia
is not mediated by effects on apolipoprotein E[J]. J Clin
Invest, 1997, 99(11):2672-2681.
[24] Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and
triglyceride levels in familial chylomicronemia syndrome[J].
N Engl J Med, 2019, 381(6):531-542.
[25] Taskinen MR, Packard CJ, Borén J. Emerging evidence
that ApoC-Ⅲ inhibitors provide novel options to reduce the
residual CVD[J]. Curr Atheroscler Rep, 2019, 21(8):27.
[26] Lazarte J, Hegele RA. Volanesorsen for treatment of familial
chylomicronemia syndrome[J]. Expert Rev Cardiovasc Ther,
2021, 19(8):685-693.
[27] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk
reduction with icosapent ethyl for hypertriglyceridemia[J]. N
Engl J Med, 2019, 380(1):11-22.
[28] Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent
ethyl on progression of coronary atherosclerosis in patients
with elevated triglycerides on statin therapy: final results of the
EVAPORATE trial[J]. Eur Heart J, 2020, 41(40):3925-3932.
[29] Clinical review report: icosapent ethyl (Vascepa): (HLS
Therapeutics Inc.)[Z]. Ottawa (ON): Canadian Agency for
Drugs and Technologies in Health, 2020.
[30] Pharmacoeconomic review report: icosapent ethyl (Vascepa):
(HLS Therapeutics Inc.)[Z]. Ottawa (ON): Canadian Agency
for Drugs and Technologies in Health, 2020.
[31] Lawler PR, Akinkuolie AO, Chu AY, et al. Atherogenic
lipoprotein determinants of cardiovascular disease and residual
risk among individuals with low low-density lipoprotein
cholesterol[J]. J Am Heart Assoc, 2017, 6(7):e005549.
备注/Memo
- 备注/Memo:
- 通信作者：王俊利， E-mail：wangjunli383639@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed145
- 全文下载/Downloads370
- 评论/Comments
